Transplantation and cytokines

Seminars in Liver Disease

Volumn 19, Issue 2, 1999, Pages 189-204

  Bumgardner, Ginny L ^a,b   Orosz, Charles G ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Cytokines; Liver; Transplantation

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

CYTOKINE RELEASE; GRAFT REJECTION; INFLAMMATION; LIVER TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 0032812319     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007109     Document Type: Review

References (140)

1. Iwatsuki S, Iwatsaki Y, Kano T, et al. Successful liver transplantation from cross-match positive donors. Transplant Proc 1981;13:286-288
2. Hanto D, Snover D, Norreen H, et al. Hyperacute rejection of a human orthotopic liver allograft in a presensitized recipient. Clin Transplant 1987;1:304-310
3. Bird G, Friend P, Donaldson P, et al. Hyperacute rejection in liver transplantation: A case report. Transplantation 1989;21: 3742-3744
4. Snover D, Freese D, Sharp H, et al. Liver allograft rejection: An analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987;11:1-10
5. Snover D. Liver transplantation. In: Sale G, ed. The Pathology of Organ Transplantation. Boston: Butterworths, 1990:103
6. Batts K, Moore S, Perkins J, et al. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988;45:376-379
7. Waldman WJ, Knight DA, VanBuskirk A, et al. Endothelial HLA class II induction mediated by allogeneic T cells activated by cytomegalovirus-infected cultured endothelial cells. Transplant Proc 1993;25:1439-1440
8. Mackay F, Loetscher H, Stueber D, et al. Tumor necrosis factor α(TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993;177:1277-1286
9. + allogeneic vascular endothelium. Transplantation 1993;56:128-134
10. Bergese SD, Pelletier R , Vallera D, et al. Regulation of endothelial VCAM-1 expression in murine cardiac grafts: Roles for TNF and IL-4. Am J Pathol 1995;146:989-998
11. Brown Z, Gerritsen ME, Carley WW, et al. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. Am J Pathol 1994;145:913-921
12. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation of pro MMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997;158:2327-2333
13. Raghow R. The role of extracellular matrix in post-inflammatory wound healing and fibrosis. FASEB J 1994;8:823-831
14. Orosz CG, VanBuskirk AM. Immune mechanisms of acute rejection. Transplant Proc 1998;30:859-861
15. Orosz CG, Bergese SD, Wakely E, et al. Acute versus chronicgraft rejection: Related manifestations of allosensitization in graft recipients. Transplant Rev 1997;11:38-50
16. VanBuskirk A, Pidwell D, Adams PW, Orosz CG. Transplantation immunology. JAMA 1997;278:1993-1999
17. Lechler R, Batchelor J. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982;155:31-41
18. Isobe M, Yagita H, Okumuru K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992;255:1125-1127
19. Isobe M, Suzuki J, Yagita H, et al. Immunosuppression to cardiac allografts and soluble antigens by anti-vascular cellular adhesion molecule-1 and anti-very late antigen-4 monoclonal anti-bodies. J Immunol 1994;153:5810-5818
20. Lenschow D, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792
21. Turka L, Linsley P, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11102-11105
22. Sempowski GD, Chess PR, Phipps RP. CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. J Immunol 1997;158: 4670-4677
23. Van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997;9:330-337
24. Rossini AA, Parker DC, Phillips NE, et al. Induction of immunological tolerance to islet allografts. Cell Transpl 1996;5:49-52
25. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995;92:9560-9564
26. Larsen C, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 Interactions play a critical role during allograft rejection. Transplantation 1996;61:4-9
27. Kirk A, Harlan D, Armstrong N, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94:8789-8794
28. Larsen C, Elwood E, Alexander D, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438
29. Mosmann T, Cherwinski H , Bond M, et al. Two types of muririe helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136: 2348-2357
30. H1 clones. J Immunol 1987;138:3688-3694
31. Cherwinski HM, Schumacher KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987;166:1229-1244
32. Mosmann T, Coffman R. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173
33. Mosmann T, Coffman R. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-147
34. + T cells and clones activated in vivo and in vitro. Immunol Rev 1991;123:85-114
35. + T cells. J Immunol 1997;158:1085-1094
36. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;180:1715-1728
37. Li L, Sad S, Kagi D, Mosmann TR. CDSTc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J Immunol 1997;158:4152-4161
38. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-282
39. + T cells into subpopulations with distinct cytokine profiles. J Immunol 1995;155: 2928-2937
40. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742
41. Chen Y, Kuchroo VK, Inobe J-I, et al. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240
42. + suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996;9:331-339
43. Talmadge J, Bowersox O, Tribble H, et al. Toxicity of tumor necrosis factor is synergistic with γ-interferon and can be reduced with cyclooxygenase inhibitors. Am J Pathol 1987;128: 410-425
44. Leist M, Gantner F, Bohlinger I. et al. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 1995;146:1220-1234
45. Krams S, Martinez O. Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis 1998;18:153-167
46. VanBuskirk AM, Wakely ME, Sirak JH, Orosz CG. Patterns of allosensitization in allograft recipients: Long-term cardiac allograft acceptance is associated with active alloantibody production in conjunction with active inhibition of alloreactive delayed-type hypersensitivity. Transplantation 1998;65:1115-1123
47. Li L. Elliott JF, Mosmann TR. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J Immunol 1994;153:3967-3978
48. Schulz, M. Schuurman HS, Joegensen J, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol 1995;25:474-180
49. Orosz CG, Bergese SD, Huang EH, VanBuskirk AM. Immunologic characterization of murine cardiac allogralt recipients with long-term graft survival due to anti-VCAM-1 or anti-CD4 monoclonal antibody therapy. Transplant Proc 1995;27:387-388
50. Orosz CG, Huang EH, Bergese SD, et al. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic-tissue remodeling. J Heart Lung Transplant 1997;16:889-904
51. Orosz CG, Wakely E, Sedmak DD, et al. Prolonged murine cardiac allograft acceptance: Characteristics of persistent active alloimmunity after treatment with gallium nitrate versus anti-CD4 monoclonal antibody. Transplantation 1997;63:1109-1117
52. Morgan CJ, Pelletier RP, Hernandez CJ, et al. Alloantigen-dependent endothelial phenotype and lymphokine mRNA expressions in rejecting murine cardiac allografts. Transplantation 1993;55:919-923
53. Takada M, Nadeau KC, Shaw GD, et al. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997;99:2682-2690
54. Colletti L, Kunkel S, Green M, et al. Hepatic inflammation following 70% hepatectomy may be related to up-regulation of epithelial neutrophil activating protein-78. Shock 1996;6: 397-402
55. Imanishi H, Scales W, Campbell D Jr. Tumor necrosis factor alpha alters the cytotoxic effect of hydrogen peroxide in cultured hepatocytes. Biochem Biophy.s Res Commun 1997;230:120-124
56. Colletti L, Kunkel S, Walz A, et al. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 1996;23:506-514
57. Halloran P, Urmson J, Van Der Meide P, Autenried P. Regulation of MHC expression in vivo. II. IFN-a/b inducers and recombinant IFN-α modulate MHC antigen expression in mouse tissues. J Immunol 1989;142:4241-4247
58. Skoskiewicz. M, Colvin R , Schneeberger E, Russell P. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by γ interferon. J Exp Med 1985;162:1645-1664
59. Chu C, Liaw Y. Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis. J Clin Pathol 1993;46:1004-1008
60. So S, Platt J, Ascher N, Snover D. Increased expression of class 1 major histocompatibility complex antigens on hepatocytes in rejection human liver allografts. Transplantation 1987;43: 79-85
61. Arias I, Jakoby W, Popper H, et al. The Liver. Biology and Pathobiology. New York: Raven Press, 1988
62. Bumgardner G, Heininger M, Li J, et al. A functional model of hepatocyte transplantation for in vivo immunologic studies. Transplantation 1998;65:53-61
63. Bumgardner G, Li J, Heininger M, et al. In vivo immunogenicity of purified allogeneic hepatocytes in a murine hepatocyte transplant model. Transplantation 1998;47-52
64. Almond PS, Bumgardner G , Chen S, Matas AJ. Pretransplant sensitization with major histocompatibility complex class 1+ class II-hepatocytes leads to accelerated skin graft rejection. J Surg Res 1992;53:182-187
65. Bumgardner G, Chen S, Hoffman R, et al. Afferent and efferent pathways in T cell responses to MHC class I+, class II-hepato-cytes. Transplantation 1989;47:163-170
66. Bumgardner G, Chen S, Almond PS, et al. Cell subsets responding to purified hepatocytes and evidence of indirect recognition of hepatocyte major histocompatibility complex class I antigen. II In vitro-generated "memory" cells to class 1+ class II;m hepatocytes. Transplantation 1992;53:863-868
67. Li J, Bumgardner G. The role of MHC antigens and adhesion molecules on in vivo cellular immune responses to allogeneic hepatocytes. Hepatology 1995;22(4) Pt II:447A (Abstract)
68. Bumgardner G, Li J, Heininger M, Orosz C. Efficacy of anti-ICAM-1 immunotherapy on immune responses to allogeneic hepatocytes. Hepatology 1998;28:1005-1012
69. Bumgardner G, Li J, Apte S, et al. Effect of tumor necrosis factor α and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology 1998;28:466-474
70. van Seventer G, Newman W , Shimizu Y, et al. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: Costimulation by purified adhesion ligands VCAM-1. ICAM-1, but not ELAM-1. J Exp Med 1991;174:901-913
71. + T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles. J Immunol 1994;153:2479-2487
72. Bacchi CE, Marsh CL, Perkins JD, et al. Expression of vascular cell adhesion molecule (VCAM-1 ) in liver and pancreas allograft rejection. Am J Pathol 1993;142:579-591
73. Lautenschlager I, Hockerstedt K. ICAM-1 induction on hepatocytes as a marker for immune activation of acute liver allograft rejection. Transplantation 1993;56:1495-1499
74. Steinhoff G, Behrend M, Schrader B, Pichlmayr R Intercellular immune adhesion molecules in human liver transplants: Overview on expression patterns of leukocyte receptor and ligand molecules. Hepatology 1993;18:440-453
75. Mochizuki K, Hayashi N, Katayama K, et al. B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology 1997;25:713-718
76. + T cells. Hepatology 1998;24:561-567
77. Inaba K, Witmer-Pack M, Inaba M. et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994;180:1849-1860
78. Coulombe M, Yang H, Guerder S, et al. Tissue immunogenicity: The role of MHC antigen and the lymphocyte costimulator B7-1. J Immunol 1996;157:4790-4795
79. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996;17:487-492
80. Bumgardner G, Li J, Heininger M, Orosz C. Costimulation pathways in host immune responses to allogeneic hepatocytes. Transplantation 1998;66:1841-1845
81. Larsen CP, Elwood ET, Alenander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438
82. Olthoff K, Judge TA, Gelman A, et al. Adenovirus-mediated gene transfer into cold-preserved liver allografts: Survival pattern and unresponsivcness following transduction with CTLA4Ig. Nature Med 1998;4:194-200
83. Yin D, Sankary H, Chong A, et al. Effect of anti-CD4 monoclonal antibody combined with human CTLA4Ig on the survival of hamster liver and heart xenografts in Lewis rats. Transplantation 1997;64:317-321
84. Kawai K, Shahinian A, Mak TW. Ohashi PS. Skin allograft rejection in CD28-deficient mice. Transplantation 1996;61:352-355
85. Noronha IL, Eberlein-Gonska M, Hartley B, et al. In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies. Transplantation 1992;54:1017-1024
86. Hancock W, Mottram PL, Pureell LJ, et al. Prolonged survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is associated with selective intragraft cytokine protein expression: Interleukin IL-4 and IL-10 but not IL-2 or interferon-gamma. Transplant Proc 1993;25:2937-2938
87. Foy TM, McIlraith M, Masters S, et al. Blockade of CD40-CD154 interferes with human T cell engraftment in scid mice. Cell Transplant 1998;7:25-35
88. Bouma GJ, Field EH. Enhanced type 2 and diminished type 1 cytokines in neonatal tolerance. Transplantation 1995;59:933-941
89. Krieger NR, Most D, Bromberg JS, et al. Coexistence of Th1-and Th2-type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance. Transplantation 1996;62:1285-1292
90. VanBuskirk AM, Wakely ME, Orosz CG. Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996;62:229-238
91. Sun J, McCaughan GW, Matsumoto Y, et al. Tolerance to rat liver allografts 1. Differences between tolerance and rejection are more marked in the B cell compared with the T cell or cytokine response. Transplantation 1994;57:1349-1357
92. Blazar B, Tuylor P, Smith S, Vallera D, Interlcukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995;85:842-851
93. Lee M, Wogensen L, Shizuru I, et al. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994;93:1332-1338
94. 1. Transplantation 1995;59:809-816
95. Qin L, Chavin KD, Ding Y, et al. Gene transfer for transplantation: Prolongation of allograft survival with transforming growth factor-bl. Ann Surg 1994;220:508-519
96. Qin L, Ding Y, Pahud D, et al. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 1997;8): 1365-1374
97. Qin L, Ding Y, Bromberg J. Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell-mediated immunity. Hum Gene Ther 1996;7:1981-1989
98. Qin L, Chavin KD, Ding Y, et al. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 1996;156:2316-2323
99. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997;350:1193-1198
100. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation . N Engl J Med 1998;338:161-165
101. Steiger J, Nickerson PW, Steurer W, et al. 1L-2 knockout recipient mice reject islet cell allografts. J Immunol 1995;155:489-498
102. Nagano H, Mitchell RN, Taylor MK, et al. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997;100:550-557
103. Piccotti JR, Chan SY, Goodman RE, et al. IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol 1996;157:1951-1957
104. Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993;259:1739-1742
105. Perkins J, Wiesner R, Banks P, et al. Immimohistologic labeling as an indicator of liver allograft rejection. Transplantation 1987; 43:105-108
106. Gouw A, Guitema S, Grond J, et al. Early induction of MHC antigens in human liver grafts. Am J Pathol 1988;133:82-94
107. McCaughan G, Davies S, Waugh J, et al. Cell surface phenotype of mononuclear cells infiltrating bile ducts during acute and chronic liver allograft rejection. Transplant Proc 1989;21:2201-2202
108. Si L, Whiteside T, VanThiel D, Rabin B. Lymphocyte subpopulations at the site of "piecemeal" necrosis in end stage chronic liver diseases and rejecting liver allografts in cyclosporine-treated patients. Lab Invest 1984;50:341-347
109. Hoffman M, Wonigeit K, Steinhoff G, et al. Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. Transplantation 1993;55:329-335
110. Martinez O, Villanueva J, Lake J, et al. IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation 1993;55:1159-1166
111. Niederkorn JY, Mellon J, Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996;37:2700-2707
112. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 1998;22:165-173
113. D'Orazio TJ, Niederkorn JY. A novel role for TGF-β and IL-10 in the induction of immune privilege. J Immunol 1998;160: 2089-2098
114. Calne R, Sells R, Pena J, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-476
115. Zhang Z, Zhu L, Quan D, et al. Pattern of liver, kidney, heart and intestine allograft rejection in different mouse strain combinations. Transplantation 1996;62:1267-1272
116. Lafferty K, Prowse S, Simeonovic C, Warren H. Immunobiology of tissue transplantation: A return to the passenger leukocyte theory. Annu Rev Immunol 1983;1:143-173
117. Gouw A, Houthoff H, Hyitema S, et al. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 1987;43:291-296
118. Gale R, Sparkes R, Golde D. Bone marrow origin of hepatic macrophage (Kupffer cells) in humans. Science 1978;201:937-938
119. Kamada N, Davies H, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981;292:840-842
120. Kamada N. The immunology of experimental liver transplantation in the rat. Immunology 1985;55:369-389
121. Kamada N, Brons G, Davies H. Fully allogeneic grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation 1980;29:429-431
122. Kamada N, Shinomiya T, Tamaki T, Ishiguro K. Immunosuppressive activity of serum from liver grafted rats: Passive enhancement of fully allogeneic heart grafts and induction of systemic tolerance. Transplantation 1986;42:581-587
123. Thai NL, Fu F, Qian S, et al. Cytokine mRNA profiles in mouse orthotopic liver transplantation. Transplantation 1995;59: 274-281
124. Tu Y, Arima T, Flye MW. Rejection of spontaneously accepted rat liver allografts with recipient interleukin-2 treatment or donor irradiation. Transplantation 1997;63:177-181
125. Bumgardner G, Roberts J, New immunosuppressive agents. Gastroenterol Clin North Am 1993;22:421-449
126. Thomson AW. The immunosuppressive macrolides FK506 and rapamycin. Immunol Lett 1991;29:105-112
127. Wood R, Katz S, Kahan B. New immunosuppressive agents. Transpl Sci 1991;1:34-46
128. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985;313:337-342
129. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;47:606-608
130. Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM. OKT3 for primary therapy of the first rejection episode in kidney transplants. Transplantation 1993;55:1023-1029
131. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993;55:766-773
132. Berlin PJ, Bacher JD, Sharrow SO, et al. Monoclonal antibodies against human T cell adhesion molecules - Modulation of immune function in nonhuman primates. Transplantation 1992;53:840-849
133. Le Mauff B, Hourmant M , Rougier J, et al. Effect of and LFA 1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991;52:291-296
134. Cooperative Clinical Trials in Transplantation Research Group. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients. A cooperative clinical trials in transplantation pilot study. Transplantation 1997;63:1243-1251
135. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991; 113:981-986
136. Dallman MJ. Cytokines as mediators of organ graft rejection and tolerance. Curr Opin Immunol 1993;5:788-793
137. Imagawa D, Millis J, Seu P, et al. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991;51:57-62
138. Seu P, Imagawa D, Wasef E, et al. Monoclonal anti-tumor necrosis factor-alpha antibody treatment of rat cardiac allografts: Synergism with low-dose cyclosporine and immunohistological studies. J Surg Res 1991;50:520-528
139. Dallman MJ, Wood KJ, Hamano K, et al. Cytokines and peripheral tolerance to alloantigen. Immunol Rev 1993;133:5-18
140. Konieczny B, Dai Z, Elwood E, et al. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998;160: 2059-2064